Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Davies, Andrew N ^a   Shorthose, K ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Muscarinic agonists *therapeutic use ; Parasympathomimetics *therapeutic use ; Pilocarpine *therapeutic use ; Radiation injuries *drug therapy ; Randomized controlled trials as topic; Salivary glands *radiation effects

Indexed keywords

BETHANECHOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; PILOCARPINE; PLACEBO; SALIVA SUBSTITUTE;

ASTHENIA; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; INDUCED HYPOTHERMIA; LACRIMATION DISORDER; MOUTH DISCOMFORT; NAUSEA; OFF LABEL DRUG USE; RADIATION HAZARD; REVIEW; RHINITIS; SALIVARY GLAND DISEASE; SIDE EFFECT; SWEATING; SYSTEMATIC REVIEW; TREATMENT RESPONSE; URINARY FREQUENCY; VASODILATATION; VISUAL DISORDER; XEROSTOMIA;

EID: 44949221219     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003782.pub2     Document Type: Review

References (47)

1. Davies 1994 {published data only} Davies AN, Singer J. A comparison of artificial saliva and pilocarpine in radiation-induced xerostomia. Journal of Laryngology and Otology 1994;108(8):663-5.
2. Johnson 1993 {published data only} Gallagher S, MacDonald J, Cullen M, Mattson P, Trivedi M. Sjogren's syndrome and radiation-induced xeroses: treatment with pilocarpine. Proceedings of 1st International Congress on Salivary Gland Diseases, Geneva, Switzerland. 2002 Jan 27-30.
3. *Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, et al.Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. New England Journal of Medicine 1993;329 (6):390-5.
4. Rieke JW, Hafermann MD, Johnson JT, LeVeque FG, Iwamoto R, Steiger BW, et al.Oral pilocarpine for radiation-induced xerostomia: Integrated efficacy and safety results from two prospective randomized clinical trials. International Journal of Radiation Oncology, Biology, Physics 1995;31(3):661-9.
5. Rieke JW, Hafermann MD, LeVeque F, Iwamoto R, Gallagher SC, Muscoplat C. Oral pilocarpine HCl (Salagen) for radiation induced xerostomia: final efficacy and safety results of prospective, randomized, placebo controlled trials. (ASTROabstract). International Journal of Radiation Oncology, Biology, Physics 1993;27(Suppl 1):175.
6. LeVeque 1993 {published data only} Gallagher S, MacDonald J, Cullen M, Mattson P, Trivedi M. Sjogren's syndrome and radiation-induced xeroses: treatment with pilocarpine. Proceedings of 1st International Congress on Salivary Gland Diseases; Geneva, Switzerland. 2002 Jan 27-30.
7. *LeVeque FG, Montgomery M, Potter D, Zimmer MB, Rieke JW, Steiger BW. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. Journal of Clinical Oncology 1993;11(6):1124-31.
8. Rieke JW, Hafermann MD, Johnson JT, LeVeque FG, Iwamoto R, Steiger BW. Oral pilocarpine for radiation-induced xerostomia: Integrated efficacy and safey results from two prospective randomized clinical trials. International Journal of Radition Oncology, Biology, Physics 1995;31(3):661-9.
9. Rieke JW, Hafermann MD, LeVeque F, Iwamoto R, Gallagher SC, Muscoplat C. Oral pilocarpine HCl (Salagen) for radiation induced xerostomia: final efficacy and safety results of prospective, randomized, placebo controlled trials. (ASTROabstract). International Journal of Radiation Oncology, Biology, Physics 1993;27(Suppl 1):175.
10. Zale M, Chambers MS, Khan Z. Pilocarpine effects on xerostomia associated with radiation therapy. (IADR abstract). Journal of Dental Research 1993;72(Spec Iss):375.
11. Cooper 1999 Cooper RA, Cowan RA, Owens SE, Jeans SP, Roberts JK, Hillel PG. Does salivary gland scintigraphy predict response to pilocarpine in patients with post-radiotherapy xerostomia?. European Journal of Nuclear Medicine 1999;26(3):220-5.
12. Epstein 1987 Epstein JB, Schubert MM. Synergistic effect of sialagogues in management of xerostomia after radiation therapy. Oral Surgery Oral Medicine Oral Pathology 1987;64(2):179-82.
13. Epstein 1994 Epstein JB, Burchell JL, Emerton S, Le ND, Silverman S. A clinical trial of bethanechol in patients with xerostomia after radiation therapy. A pilot study. Oral Surgery Oral Medicine Oral Pathology 1994;77(6):610-4.
14. Ferguson 1991 Ferguson MM, Hayes P, Highton J, Jones DS, MacFadyen EE, Palmer DG. Pilocarpine oral solution. British Dental Journal 1991;170(7):251.
15. Fox 1991 Fox PC, Atkinson JC, Macynski A, Wolff A, Kung DS, Shiroky J, et al.Pilocarpine for treatment of salivary hypofunction - a six month trial. (AADR abstract). Journal of Dental Research 1989;68 (spec iss): 315.
16. *Fox PC, Atkinson JC, Macynski AA, Wolff A, Kung DS, Valdez IH, et al.Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Archives of Internal Medicine 1991;151(6):1149-52.
17. Frydrych 2002 Frydrych AM, Davies GR, Slack-Smith LM, Heywood J. An investigation into the use of pilocarpine as a sialagogue in patients with radiation induced xerostomia. Australian Dental Journal 2002;47(3): 249-53.
18. Gorsky 2004 Gorsky M, Epstein JB, Parry J, Epstein MS, Le ND, Silverman Jr S. The efficacy of pilocarpine and bethanechol upon saliva production in cancer patients with hyposalivation following radiation therapy. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics 2004;97(2):190-5.
19. Greenspan 1987 *Greenspan D, Daniels TE. Effectiveness of pilocarpine in postradiation xerostomia. Cancer 1987;59(6):1123-5.
20. Greenspan D, Daniels TE. The use of pilocarpine in post-radiation xerostomia. (IADR abstract). Journal of Dental Research 1979;58 (spec iss A):420.
21. Hamlar 1996 Hamlar DD, Schuller DE, Gahbauer RA, Buerki RA, Staubus AE, Hall J. Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma. Laryngoscope 1996;106(8):972-6.
22. Horiot 2000 *Horiot JC, Lipinski F, Schraub S, Maulard-Durdux C, Bensadoun RJ, Ardiet JM. Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. Radiotherapy and Oncology 2000;55(3):233-9.
23. Horiot JC, Lipinski F, Schraub S, Maylin C, Bensadoun RJ, Ardiet JM. Post radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. (ECCO abstract). European Journal of Cancer 1997;33((Suppl 8)):S16.
24. Horiot JC, Lipinski F, Schraub S, Maylin C, Bensadoun RJ, Gerard JP. Can pilocarpine hydrochloride relieve xerostomia regardless of the destruction of major salivary glands? A prospective French cooperative study. (ESTRO abstract). Radiotherapy and Oncology 1996;40((Suppl 1)):S41.
25. Jacobs 1996 Jacobs CD, Van Der Pas M. A multicenter maintenance study of oral pilocarpine tablets for radiation-induced xerostomia. Oncology (Huntington) 1996;10(3 Suppl):16-20.
26. Joensuu 1993 Joensuu H, Bostrom P, Makkonen T. Pilocarpine and carbacholine in treatment of radiation-induced xerostomia. Radiotherapy and Oncology 1993;26(1):33-7.
27. Leek 2002 Leek H, Albertsson M. Pilocarpine treatment of xerostomia in head and neck patients. Micron 2002;33(2):153-5.
28. MacCarthy 1998 MacCarthy D, Moriarty M, Waldron D. Baseline dental status of post head and neck radiation patients. (IADR abstract). Journal of Dental Research 2000;79(5):1229.
29. *MacCarthy D, Moriarty M, Waldron D. The use of pilocarpine HCl in patients with post-radiation xerostomia - Report of a pilot study. (IADR abstract). Journal of Dental Research 1998;77(Spec Iss B):979.
30. Matsumoto 2000 Matsumoto Y. (Research on delayed damage after radiation therapy for head and neck patients). Shika Igaku 2000;63(1):15-22.
31. Mosqueda-Taylor 2004 Mosqueda-Taylor A, Luna-Ortiz K, Irigoyen-Camacho ME, Diaz-Franco MA, Coll-Munoz AM. Effect of pilocarpine hydrochloride on salivary production in previously irradiated head and neck cancer patients [Efecto del clorhidrato de pilocarpina como estimulante de la produccion salival en pacientes sometidos a radioterapia de cabeza y cuello]. Medicina Oral 2004;9(3):204-11.
32. Schuller 1989 Schuller DE, Stevens P, Clausen KP, Olsen J, Gahbauer R, Martin M. Treatment of radiation side effects with oral pilocarpine. Journal of Surgical Oncology 1989;42(4):272-6.
33. Singhal 1997 Singhal S, Powles R, Treleaven J, Rattenbury H, Mehta J. Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. Leukemia and Lymphoma 1997;24(5-6):539-43.
34. Szabo 1985 Szabo G. Treatment of xerostomia with pilocarpine. Based on 15 years experience and treatment of 500 patients [Xerostomia kezelese Pilocarpinnal]. Fogorvosi Szemle 1985;78(3):65-9.
35. Aromdee 1996 Aromdee C, Fawcett JP, Ferguson MM, Ledger R. Serumpilocarpine esterase activity and response to oral pilocarpine. Biochemical and Molecular Medicine 1996;59(1):57-61.
36. Bjornstrom 1990 Bjornstrom M, Axell T, Birkhed D.Comparison between saliva stimulants and saliva substitutes in patients with symptoms related to dry mouth. A multi-centre study. Swedish Dental Journal 1990;14 (4):153-61.
37. Chambers 2005 Chambers M, Garden A, Lemon J, Kies M, Martin J. Oral complications of cancer treatment. In: DaviesA, FinlayI editor(s). Oral care in advanced disease. Oxford: Oxford University Press, 2005:171-84.
38. Davies 1997 Davies AN. The management of xerostomia: a review. European Journal of Cancer Care 1997;6(3):209-14.
39. Dawes 1987 Dawes C. Physiological factors affecting salivary flow rates, oral sugar clearance, and the sensation of dry mouth in man. Journal of Dental Research 1987;66(Spec Iss):648-53.
40. Guchelaar 1997 Guchelaar H-J, Vermes A, Meerwaldt JH. Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. Supportive Care in Cancer 1997;5(4):281-8.
41. Jadad 1996 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
42. Navazesh 1992 Navazesh M, Christensen C, Brightman V. Clinical criteria for the diagnosis of salivary gland hypofunction. Journal of Dental Research 1992;71(7):1363-9.
43. Pankhurst 1996 Pankhurst CL, Smith EC, Rogers JO, Dunne SM, Jackson SH, Proctor G. Diagnosis and management of the dry mouth: Part 1. Dental Update 1996;23(2):56-62.
44. Sreebny 1996 Sreebny LM. Xerostomia: diagnosis, management and clinical complications. In: EdgarWM, O'MullaneDM editor(s). Saliva and oral health. 2nd Edition. London: British Dental Association, 1996:43-66.
45. Tavender 2004 Tavender EJ, Davies AN, Glenny AM. Pharmacological interventions for preventing salivary gland dysfunction following radiotherapy. Cochrane Database of Systematic Reviews 2004, Issue 3.Art. No.: CD004940. DOI:10.1002/14651858.CD004940.
46. Valdez 1993 Valdez IH, Wolff A, Atkinson JC, Macynski AA, Fox PC. Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer 1993;71(5):1848-51.
47. Wiseman 1995 Wiseman LR, Faulds D. Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs 1995;49(1):143-55.